Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a leading American biotechnology company focused on discovering, developing, and commercializing innovative medicines for serious diseases. Founded in 1988 and headquartered in Tarrytown, New York, USA, the company has earned global recognition for its science-driven approach to drug discovery and biologics development. Regeneron integrates advanced genetics, artificial intelligence, high-throughput research, and proprietary antibody technologies to accelerate the development of life-changing therapies.

The company’s portfolio spans ophthalmology, oncology, immunology, cardiovascular diseases, rare genetic disorders, infectious diseases, and inflammation. Its VelociSuite® technology platform has enabled the rapid discovery and development of multiple monoclonal antibody therapies that have become standard treatments in several therapeutic areas. Regeneron also collaborates extensively with pharmaceutical companies, academic institutions, and healthcare organizations worldwide to expand scientific innovation and improve patient outcomes.

With manufacturing facilities and research campuses primarily in the United States and additional international operations, Regeneron maintains rigorous quality standards and regulatory compliance across its global network. The company is committed to sustainability, ethical business practices, and continuous investment in scientific research. Through ongoing clinical trials and breakthrough innovations, Regeneron continues to strengthen its position as one of the world’s most respected biotechnology companies, delivering advanced biologic medicines to patients across more than 100 countries.